Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Motilal Oswal 19th Annual Global Investor Conference to be held on August 23, 202317-08-2023
17-08-2023
Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Avendus Spark Investor Conference to be held on August 16, 202310-08-2023
Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of the earnings call hosted on July 27, 202301-08-2023
Buy Laurus Labs; target of Rs 410: Motilal Oswal
Motilal Oswal is bullish on Laurus Labs recommended buy rating on the stock with a target price of Rs 410 in its research report dated July 27, 2023.31-07-2023
Laurus Labs share price falls 3% after weak Q1 results; Should you buy, sell or hold?
Laurus Labs Q1 results were impacted by lower sales, operational deleverage and elevated expenses.28-07-2023
Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Audio recording of the earnings conference call hosted on July 27, 202327-07-2023
Q1FY24 Quarterly Result Announced for Laurus Labs Ltd.
Pharmaceuticals company Laurus Labs announced Q1FY24 results: Revenue at Rs 1,182 crore, down 23% YoY EBITDA at Rs 168 crore, down 63% YoY EBITDA margins at 14.2% PAT at Rs 25 crore, down 90% YoY PAT margins at 2.1% EPS (Diluted) for the period at Rs 0.5 per share (not annualised) Commenting on the highlights, Founder and Chief Executive Officer Dr. Satyanarayana Chava stated, “While our operating results this quarter were primarily impacted by lower sales, operational deleverage and elevated expenses, the underlying demand for key growth portfolio within Non-ARVs generics and CDMO progress remains strong and healthy. ARV business has incrementally stabilised on an overall basis and therefore we remain optimistic about our H2 growth prospects as indicated earlier. During the quarter, Laurus continued to advance its R&D-driven; commercial strategy by successfully signing its first multi-year commercial partnership in Crop Science and further deepening its commitment to the emerging CGT technology platform. Our CDMO growth projects are on track with an Animal Health manufacturing block commissioned recently and a dedicated R&D; center coming online in late FY24. We remain committed to ensuring greater business resilience and long-term performance, with growing scientific capabilities remaining the source of our company’s energy and value creation.” Commenting on the results, V V Ravi Kumar, Executive Director & Chief Financial Officer said, “We delivered a subdued financial performance for Q1FY24. We achieved Rs 1,182 crore in revenues, representing a 23% decline, and Rs 168 crore EBITDA, resulting in a 14.2% margin. Performance was mainly affected by operational deleverage, material drop in the CDMO business, and price fall in the ARV portfolio over last year. We are anticipating a rebound from H2, with recovering revenue trends, positives from cost improvement programs, and raw material price stabilisation. Our future capex projects towards strengthening CDMO and Bio division are advancing as per the schedule and Debt leverage position remains comfortable” Result PDF27-07-2023
Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release Q1 FY 2427-07-2023
Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation Q1 FY 2427-07-2023